CEO Executive AssistantWomen’s health remains one of the most chronically underfunded corners of biomedical research. The conditions that affect hundreds of millions of women globally, including endometriosis, polycystic ovary syndrome (PCOS), and menopause-related disorders, have historically received a fraction of the research investment directed at conditions of comparable prevalence. For pharma and biotech CEOs building or scaling a women’s health portfolio, that gap is both the opportunity and the operational challenge. The question is not whether to invest here. The question is how you personally allocate your time to convert that investment into durable competitive advantage.
This is not a standard portfolio governance conversation. Women’s health carries regulatory pathway nuances, patient advocacy dynamics unlike any other disease area, payer access barriers rooted in historical undervaluation, and organizational culture dimensions that report directly to the CEO. Delegating any of these domains without direct executive ownership creates compounding risk. What follows is a practical framework for how pharma CEOs should think about their time allocation when leading in this space.
Why Women’s Health Demands CEO-Level Time Investment
Before getting to the time allocation model, it is worth being precise about why women’s health is different. Many disease areas require external engagement, regulatory navigation, and commercial creativity. Women’s health requires all three simultaneously, in a context where institutional skepticism has historically been the default, not the exception.
Clinical trial design in women’s health has suffered from decades of exclusion. The FDA’s 1977 guidance excluding women of childbearing potential from Phase I and early Phase II trials created a legacy that still shapes how researchers, payers, and regulators approach evidence standards in this space. Overcoming that legacy requires CEOs who understand it well enough to make credible commitments, not just to invest in research, but to design studies that generate data payers and regulators can act on.
The reputational dimension compounds this. A biotech CEO who positions a product in the endometriosis market without genuinely understanding the patient experience risks serious organizational and commercial damage. Patient communities in women’s health are highly informed, highly networked, and increasingly influential with regulators. They are partners, not audiences. CEOs who treat them as audiences lose in this market.
Time Allocation Framework: The Four Domains
Domain 1: Pipeline Governance and Scientific Oversight
Pipeline governance in women’s health requires more direct CEO involvement than in most other disease areas, because the science is genuinely early-stage in many indications. Endometriosis, for example, lacks validated biomarkers, has no disease-modifying therapy approved to date, and still relies primarily on surgical diagnosis in many healthcare systems. PCOS encompasses a heterogeneous patient population where the underlying biology remains incompletely understood. These are not polished pipeline opportunities with clear regulatory precedents. They are frontier science that requires a CEO with scientific literacy and governance discipline.
You should be spending direct time on pipeline governance decisions at least monthly, not just receiving summary updates. This means sitting in scientific advisory board sessions when women’s health programs are reviewed, understanding the mechanism-of-action rationale for your lead assets, and being able to articulate to your board why a Phase II readout met or missed the mark. When your Chief Medical Officer or Chief Scientific Officer presents a go/no-go decision on a women’s health program, your role is not to ratify their judgment. It is to pressure-test it.
This matters more in women’s health because the field lacks the comparative data density available in oncology or cardiovascular disease. Your scientific team will be making judgment calls with less external benchmarking than they would in other areas. The CEO must be close enough to calibrate confidence appropriately.
Practically, this means blocking two to three hours per month for direct scientific deep-dives on women’s health assets, separate from standard pipeline review meetings. It means reading, not just receiving, the key data packages before major decision points. And it means building a personal network of external scientific advisors in reproductive endocrinology, gynecologic oncology, and related fields, so your judgment is not entirely dependent on internal perspectives.
Domain 2: Regulatory Strategy and Pathway Development
The FDA’s Office of Women’s Health and the corresponding bodies at EMA have become increasingly sophisticated about women’s health, but the regulatory pathway for many indications remains under construction. For conditions like endometriosis, there is no universally accepted primary endpoint for pivotal trials. For menopause-related conditions, the clinical meaningfulness of vasomotor symptom measures is still debated. For PCOS, the question of which patient subgroup to target in a registrational trial is genuinely contested.
This is not a regulatory affairs team problem. This is a CEO problem. The choices your team makes about regulatory strategy will define the competitive position of your asset for a decade. A CEO who is not personally engaged in the endpoint strategy discussions, the pre-IND and Type B meeting preparation, and the advisory committee positioning is abdicating a core strategic responsibility.
Direct engagement with regulatory strategy oversight is essential here. This does not mean attending every regulatory meeting. It means being present for the pivotal strategy decisions, understanding the agency’s historical feedback on comparable programs, and being willing to make the call when your regulatory and commercial teams disagree about trial design tradeoffs.
One specific area deserving direct CEO attention is the risk-benefit communication strategy for reproductive health indications. Contraceptive side effects, teratogenicity risk, menstrual cycle impacts: these are areas where label language has enormous commercial and reputational consequences. Decisions about how to communicate risk to patients and prescribers, and how to engage with advocacy groups on those communications, should not be made without CEO involvement.
Practically, plan for quarterly direct engagement with your regulatory team on women’s health programs, including a personal review of FDA correspondence and a standing conversation with your Head of Regulatory Affairs about agency posture on your lead indications.
Domain 3: Patient Advocacy and Community Engagement
This is the domain where most pharma CEOs underinvest their personal time, and it is the domain where underinvestment causes the most lasting damage in women’s health. Patient communities in endometriosis, PCOS, and menopause are not passive stakeholders. Organizations like the Endometriosis Foundation of America, RESOLVE (the National Infertility Association), and the Menopause Society have substantial public credibility and direct relationships with the clinicians, payers, and policymakers your commercial success depends on.
A CEO who engages personally with these communities, speaks at their conferences, learns their specific concerns about trial design and access, and builds genuine relationships with their leadership is doing something that cannot be delegated. A Chief Patient Officer or VP of Patient Advocacy can manage the ongoing relationship. But the signal sent when a CEO shows up personally, and when they demonstrate actual knowledge of the condition rather than prepared talking points, is categorically different. It builds trust that translates into co-design of clinical trials, support for regulatory submissions, and advocacy with payers.
The time investment here is manageable: two to four patient advocacy engagements per year at the CEO level, plus quarterly briefings from your patient advocacy team on community concerns related to your specific programs. What matters is depth, not frequency. A single substantive conversation with the leadership of a major endometriosis advocacy organization, where you genuinely listen to their concerns about diagnostic delays and inadequate treatment options, is worth more than five appearances at industry panels.
Be specific about what you are learning and what you are acting on. Patient advocates in women’s health have been disappointed by pharma promises before. Credibility is built through action, and the CEO is the only person who can make the commitments that demonstrate your organization’s long-term seriousness.
Domain 4: Payer Access and Market Development
Payer access in women’s health is structurally harder than in most other therapeutic areas. Historically, many payers have categorized women’s health treatments as elective or lifestyle-related, applying stricter utilization management than they would to conditions of comparable burden in male or mixed-sex populations. This is changing, driven by employer benefit design innovation and evolving policy frameworks, but the change is slow and uneven.
As CEO, you need to be personally engaged in payer strategy in a way that goes beyond reviewing market access plans. The commercial case for women’s health treatments requires narrative building at the payer leadership level, and that narrative has to come from the CEO. This means direct engagement with the Chief Medical Officers and pharmacy directors of major commercial payers and PBMs, conversations that your market access team cannot have at the same level of credibility or authority.
McKinsey research on women’s health market development has consistently found that employer benefit innovation is outpacing traditional payer reform in this space. Large self-insured employers are actively looking to differentiate their benefits packages with women’s health coverage, and they are willing to engage with CEOs directly about access and pricing structures. A CEO who builds five to ten direct relationships with Chief People Officers and Chief Benefits Officers at major employers can shape the access environment for their products in ways that a commercial team working through traditional channels cannot.
Practically, this means carving out time annually for five to six direct payer and employer engagement meetings, with your Chief Commercial Officer and market access team doing the preparation work and the CEO conducting the relationship-building conversation.
The Culture and Reputation Dimension: Why This Reports to You
Women’s health is one of the few therapeutic areas where the internal culture of your organization is a material business variable. Teams working in women’s health, particularly researchers who have built their careers in historically underfunded areas, are watching how seriously leadership takes this work. If your women’s health pipeline is treated as a secondary priority in resource allocation discussions, your ability to attract and retain the scientific and clinical talent that this area demands will be compromised.
This means CEO visibility inside the organization matters as much as external engagement. Speaking at internal women’s health program reviews, publicly acknowledging the team when a clinical milestone is reached, and being explicit in all-hands conversations about why women’s health is a strategic priority, not a social initiative, are not peripheral responsibilities. They are core to executing your strategy.
The reputational dimension extends to how you communicate externally about the commercial rationale for your women’s health programs. There is a legitimate conversation to be had about the fact that women’s health is also a large and underserved market with substantial revenue potential. Having that conversation honestly, acknowledging both the commercial opportunity and the moral dimension of addressing historically neglected conditions, is more credible than either pure altruism or pure commercialism. CEOs who can hold both frames authentically earn the trust of both investors and patient communities.
Building the Right Time Architecture
The total time investment described above is approximately 15 to 20 percent of a pharma CEO’s working time for an organization with women’s health as a primary strategic focus. For organizations where women’s health is one of several major therapeutic areas, a 10 to 12 percent allocation is realistic.
The key is not total hours but structure. Ad hoc CEO engagement in women’s health produces ad hoc results. The organizations winning in this space are building systematic CEO engagement models: quarterly pipeline governance sessions with direct scientific review, standing patient advocacy briefings, scheduled payer engagement calendars, and regular internal visibility moments that signal sustained strategic priority.
According to a 2023 McKinsey analysis, closing the women’s health gap represents a $1 trillion global economic opportunity, a figure that reflects both the scale of unmet need and the commercial potential available to organizations that invest seriously. CEOs who build the personal engagement model to lead effectively in this space will be positioned to capture a disproportionate share of that opportunity.
What This Requires From You Personally
The pharma CEO building a women’s health portfolio needs three things that are harder to schedule than meetings. First, genuine scientific curiosity about conditions that have been systematically under-studied: the willingness to sit with ambiguity and make decisions with less evidence than you would have in a more mature therapeutic area. Second, the relational credibility to engage authentically with patient communities that have been disappointed by pharma before. Third, the organizational authority to protect women’s health programs in resource allocation battles, particularly during pipeline prioritization cycles when conditions without large established markets are vulnerable to deferred investment.
These are not qualities that can be developed in board presentations. They are built through sustained, direct personal engagement with the science, the patients, and the commercial landscape. The CEOs building durable competitive positions in women’s health are the ones who made that engagement a structural feature of their role, not an occasional priority.